First human trial launches for promising blood cancer drug duo
NCT ID NCT03326310
Summary
This early-stage study is testing a new combination of two drugs, selumetinib and azacitidine, for adults with higher-risk chronic myeloid blood cancers like myelodysplastic syndromes (MDS) and myelofibrosis. The main goal is to find the safest and most effective dose by carefully monitoring patients for side effects. The trial will enroll about 18 people who have not responded well to other treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The University of Chicago
RECRUITINGChicago, Illinois, 60637, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.